髓鞘少突胶质细胞糖蛋白
实验性自身免疫性脑脊髓炎
多发性硬化
免疫抑制
自身免疫性疾病
微嵌合体
自身免疫性甲状腺炎
医学
免疫学
疾病
甲状腺炎
生物
抗体
内科学
遗传学
胎儿
怀孕
作者
Justin D. Glenn,Itzy E. Morales Pantoja,Patrizio Caturegli,Katharine A. Whartenby
标识
DOI:10.1016/j.jneuroim.2019.577115
摘要
Multiple sclerosis (MS) is an autoimmune disease that remains in need of effective therapies. Plant-derived medicines have appealing properties for the treatment of autoimmune diseases. MYMD-1 is a synthetic plant alkaloid that has been shown to ameliorate the course of autoimmune thyroiditis. The goal of the present study was to determine whether MYMD-1 would produce similar beneficial effects in a mouse model of MS, experimental autoimmune encephalomyelitis (EAE) induced by immunization with myelin oligodendrocyte glycoprotein. MYMD-1 improved the course of EAE and suppressed activation of effector T cells without causing global immunosuppression or toxicity. These results suggest that MYMD-1 may be of interest for evaluating for the treatment of autoimmune diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI